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Open access under CC BY-NC-ND license.Pirfenidone, an orally active small molecule, is an immunosup-
pressant that is thought to have anti-inﬂammatory and antiﬁb-
rotic effects both in vitro and in vivo [1–5]. Although various
combinations of medications have been introduced over the
past years for the treatment of idiopathic pulmonary ﬁbrosis
(IPF), yet no therapy has proven to improve survival. Follow-
ing evaluation in Phase II and Phase III clinical trials in
patients with IPF [6–8], pirfenidone was approved by the
European Commission in February 2011. Its mechanism of
action is not fully understood but it is likely that pirfenidone
exerts its effects by suppressing ﬁbroblast proliferation, reduc-
ing the production of ﬁbrosis-associated proteins and cyto-
kines and reducing the response to growth factors such as
transforming growth factor-beta and platelet-derived growth
factor [9]. In the lung, pirfenidone reduced ﬁbrosis in response
to bleomycin, lung transplant and repeated allergen exposure
[5]. Pirfenidone is the ﬁrst substance for which more than
one positive phase III randomised, placebo-controlled trial
has been reported with a statistically signiﬁcant effect on a pri-
mary end-point in patients with IPF.
A decline in both relative and absolute changes in the
forced vital capacity (FVC) has been shown consistently to
predict mortality in patients with IPF [10–12]. Pirfenidone
has been shown to reduce the decline in FVC in patients with
IPF. Therefore, it is recommended as an option for treating
IPF only if the predicted FVC is between 50% and 80%.
Treatment with pirfenidone should be discontinued if there is
evidence of disease progression (a decline in percent predicted
FVC of 10% or more within any 12 month period) [9].
It is noted that the most commonly reported (10% or
greater) adverse effects of pirfenidone (2403 mg/day) com-
pared with placebo were nausea (32.8% compared with
13.3%), rash (28.7% compared with 8.6%), fatigue (22.3%
compared with 13.3%), diarrhoea (21.7% compared with
13.5%), dyspepsia (16.8% compared with 5.5%), and photo-
sensitivity reaction (12.2% compared with 1.7%). These
adverse events were consistent with the known safety proﬁle
of pirfenidone and were usually mild to moderate in severity
[6]. The average annual cost of ongoing treatment with pirfeni-
done is £26,171.72 [9]. Thus, cost-beneﬁt analysis andcost-effectiveness of using pirfenidone in IPF patients should
be thoroughly evaluated before the start of treatment.Conﬂict of interest
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